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Background: The role of interleukin (IL)-23 in asthma pathophysiology is still controversial. We exam-
ined its role in allergic airway inﬂammation in response to two distinct antigens using IL-23-deﬁcient
mice.
Methods: Allergic airway inﬂammation was evaluated in wild-type and IL-23p19/ mice. Mice were
sensitized to ovalbumin (OVA) or house dust mite (HDM) by intraperitoneal injection of antigen and their
airways were then exposed to the same antigen. Levels of antigen-speciﬁc immunoglobulins in serum as
well as cytokines in bronchoalveolar or peritoneal lavage ﬂuid and lung tissue were determined by
enzyme-linked immunosorbent assay and/or quantitative polymerase chain reaction.
Results: Deﬁciency of IL-23p19 decreased eosinophils and Th2 cytokines in bronchoalveolar lavage ﬂuid
(BALF) of OVA-treated mice, while it increased BALF eosinophils of HDM-treated mice. Peritoneal in-
jection of OVA with alum, but not of HDM, induced local synthesis of IL-6, IL-10, and IL-23. Systemic
production of antigen-speciﬁc IgG1 was partially dependent on IL-23. In contrast, airway exposure to
HDM, but not to OVA, induced IL-23p19 mRNA expression in the lungs. In IL-23p19-deﬁcient mice, HDM-
exposed lungs did not exhibit the induction of IL-17A, which negatively regulates eosinophilic
inﬂammation.
Conclusions: Different antigens induced IL-23 at different part of the body in our similar asthma models.
Endogenous IL-23 production at the site of antigen sensitization facilitates type-2 immune responses,
whereas IL-23 production and subsequent IL-17A synthesis in the airways suppresses allergic
inﬂammation.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.dicine, Department of Medi-
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Bronchial asthma is a chronic inﬂammatory disease of the air-
ways characterized by eosinophilic inﬁltrates, mucus hypersecre-
tion, airway remodeling, and bronchial hyperresponsiveness.1
Allergic airway inﬂammation is primarily driven by allergen-
speciﬁc CD4þ T cells. Upon allergen presentation by dendritic
cells, naïve CD4þ T cells differentiate into four distinct populations
depending on the cytokine environment: T helper cell type 1 (Th1),
Th2, Th17, and regulatory T cells. Asthma is accompanied by theevier B.V. All rights reserved.
R. Ogawa et al. / Allergology International 64 (2015) S24eS29 S25induction of antigen-speciﬁc Th2 cells and related cytokines such as
interleukin (IL)-4, IL-5, and IL-13.2e4 Recent studies have shown
that Th17 cells and related cytokines, including IL-17A, IL-17F, and
IL-22, are also associated with allergic inﬂammation.5 In asthmatic
patients, IL-17A concentration is increased in peripheral blood,
sputum, and bronchoalveolar lavage ﬂuid (BALF).6e8 In experi-
mental models of asthma, Th17 cells enhance not only neutrophilic
airway inﬂammation8 but also Th2 cell-mediated eosinophilic
airway inﬂammation.9
IL-23, secreted from antigen-presenting cells such as activated
macrophages and dendritic cells, is an essential cytokine in the
maintenance of Th17 cells, secretion of IL-17A, and memory T-cell
proliferation.5,9e14 Recently, Wakashin et al.9 found that IL-23 en-
hances antigen-induced Th2 cytokine production and eosinophil
recruitment in airways. Peng et al.15 reported the activation of IL-23
receptors expressed on Th2 cells promotes Th2 polarization and
cytokine production. These results suggest important roles for IL-23
in the development of asthma. Conversely, there are some reports
that provide evidence for IL-23 and/or IL-17A as negative regulators
of allergic inﬂammation.16,17 IL-23 suppresses inﬂammatory re-
sponses to fungi in the airways in a toll-like receptor (TLR) 6-
dependent manner, which includes the activation of T cells, Th2
cytokine production, and granulocyte recruitment.17
The precise roles of the IL-23/Th17 axis in the regulation of
allergic airway inﬂammation are still controversial. Thus, we per-
formed this study using IL-23 deﬁcient (IL-23p19/) mice in two
different models of asthma.
Methods
Animal preparations
Speciﬁc pathogen- and viral antibody-free, 6-week-old, female
C57BL/6J (WT)miceweighing between 20 and 25 gwere purchased
from Charles River Laboratories (Yokohama, Japan). IL-23-deﬁcient
(IL-23p19/) and IL-17A-deﬁcient (IL-17A/) mice with a C57BL/6
genetic background were developed as previously reported.18,19 All
animals were housed in a facility in bioBubble® barrier units (bio-
Bubble Inc., Fort Collins, CO) under positive pressure. The experi-
mental protocol was reviewed and approved by the Laboratory
Animal Care and Use Committee of Keio University School of
Medicine.
Allergen sensitization and exposure
In the ovalbumin (OVA)-induced airway inﬂammation model,
sensitization to OVA was achieved by intraperitoneal injection of
15 mg OVA in an alum solution (Imject®Alum, Pierce Chemical,
Rockford, IL) on days 0, 7, and 14. Airway challenge was carried out
in a dedicated chamber with aerosolized 1% (w/v) OVA diluted in
phosphate buffered saline (PBS) for 20 min on days 21, 22, 23, and
24.
In the house dust mite antigen (HDM)-induced airway inﬂam-
mation model, mice were actively sensitized against Dermatopha-
goides pteronyssinus antigen (Biostir, Kobe, Japan) by
intraperitoneal injection of 10 mg HDM on days 0, 7, and 14. On days
21, 22, and 23, themicewere exposed to HDM (100 mg/body) via the
nares. Mice treated with PBS were used as controls.
Bronchoalveolar and peritoneal cavity lavage ﬂuid
Mice were sacriﬁced by giving an intraperitoneal overdose of
pentobarbital 24 h after the ﬁnal OVA or HDM airway exposure. The
trachea was cannulated and the lungs were lavaged with 1.4 ml of
cold PBS containing 0.6 mM ethylenediamine tetraacetic acid(EDTA) to collect bronchoalveolar lavage ﬂuid (BALF). In some an-
imals, the peritoneal cavity was lavaged with 5 ml of PBS/EDTA 3, 6,
12, and 24 h after an OVA or HDM peritoneal injection.
The cells in BALF and the abdominal cavity lavage ﬂuid were
counted using a hemocytometer, and white blood cell differential
counts were determined on Diff-Quik-stained cytospin slides
(Symex, Kobe, Japan).
Cytokine analysis
The concentrations of cytokines in BALF and peritoneal lavage
ﬂuid were measured with an ELISA kit (R&D Systems, Minneapolis,
MN, USA) according to the manufacturer's instructions.
Measurement of serum ova- and hdm-speciﬁc IgG1 antibodies in
serum
Blood was collected from the inferior vena cava 24 h after the
last challenge of antigens in the airways. OVA IgG1 was measured
using a commercially available ELISA kit (Shibayagi, Gunma, Japan),
according to the manufacturer's instructions. HDM-speciﬁc IgG1
antibody in serum was measured by direct ELISA using target
antigen-coated plates, biotinylated anti-mouse IgG1 rat antibody
(BD Biosciences, San Jose, CA, USA) and avidin-peroxidase (Sig-
maeAldrich, St. Louis, MO, USA). Protein concentration was deter-
mined by measuring the optical density at 450 nm after color
development with 3,30,5,5'-tetramethylbenzidine Substrate Re-
agent Set (BD Biosciences), which was stopped by the addition of
1 M H2SO4.
Quantitative real-time RT-PCR
Tissue samples were homogenized and total RNA was extracted
using the RNeasy Mini kit (QIAGEN, Hilden, Germany). Comple-
mentary DNAwas generatedwith SuperScript reverse transcriptase
(Invitrogen, Carlsbad, CA, USA). The expression level of mRNA was
measured by real-time quantitative PCR using SYBR Green Master
Mix (Applied Biosystems, Foster City, CA, USA) and an ABI 7500
Real-Time PCR System (Applied Biosystems). We used the DD
threshold cycle (ddCt) technique to calculate relative mRNA
expression of target genes normalized to levels of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene.
Statistical analysis
Data are presented as means ± SEM. Student's t-test and one-
way analysis of variance were performed for comparisons of two
and three or more groups, respectively. Tukey's tests for compari-
son with control group and Dunett's multiple comparison tests for
analysis among groups without control group were used as post-
hoc tests. Data were analyzed with GraphPad Prism 6 (GraphPad
Software, La Jolla, CA, USA). A p value less than 0.05 was regarded as
signiﬁcant.
Results
IL-23 promotes ova-induced asthmatic responses
In order to examine the roles of IL-23, we compared OVA-
induced airway inﬂammation in IL-23p19/ mice with that of
wild-type mice (Fig. 1). Although both types of animals exhibited
eosinophilic inﬂammation in response to OVA exposure in the
airways, IL-23p19/ mice had less eosinophils in the BALF than
wild-type mice (Fig. 1a, b). The amounts of IL-5 and IL-13 in BALF
were also reduced by half in IL-23p19/ mice (Fig. 1c, d, P < 0.01).
Fig 1. Ovalbumin (OVA)-induced asthma model. Wild-type (WT) and IL-23p19/ (IL-23/) mice were sensitized to OVA intraperitoneally and then exposed to aerosolized OVA or
phosphate buffered saline (PBS) in the airways. Total (a) and differential (b) cell counts in bronchoalveolar lavage ﬂuid were examined 24 h after the ﬁnal OVA exposure (n ¼ 29 for
WT, n ¼ 29 for IL-23/). The concentration of IL-5 (c) and IL-13 (d) in the bronchoalveolar lavage ﬂuid was determined by ELISA (n ¼ 9e16). Mean þ SEM. *P < 0.05 compared to
wild-type mice.
Fig. 2. House dust mite antigen (HDM)-induced asthma model. Wild-type (WT) and IL-23p19/ (IL-23/) mice were sensitized to HDM intraperitoneally and then exposed to
HDM or phosphate buffered saline (PBS) via the nares. Total (a) and differential (b) cell counts in bronchoalveolar lavage ﬂuid were examined 24 h after the ﬁnal HDM exposure
(n ¼ 7 for WT, n ¼ 3 for IL-23/). The concentration of IL-5 (c) and IL-13 (d) in the bronchoalveolar lavage ﬂuid was determined by ELISA (n ¼ 3e7). Mean þ SEM. *P < 0.05
compared to wild-type mice.
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To conﬁrm the asthma-promoting effects of IL-23, we sensitized
and exposed mice to HDM antigen, one of the most clinically
important allergens, using a similar protocol. In contrast to our
expectation, IL-23p19/ mice exhibited signiﬁcantly higher
numbers of eosinophils in the BALF thanwild-type animals (Fig. 2a,
b, P < 0.05). Neutrophilic inﬂammation was also observed in HDM-
treated mice; however, no difference was observed in the number
of BALF neutrophils between wild-type and IL-23p19/ mice.
Cytokine production induced by HDM was also examined (Fig. 2c,Fig. 3. Production of IL-23 and other cytokines in the peritoneal cavity in response to ovalbu
washed 3, 6, 12, and 24 h after antigen injection (n ¼ 3). Mean ± SEM. *P < 0.05 compared to
collected 24 h after antigen challenge were examined in wild-type (WT) and IL-23p19/ (d). A propensity for both IL-5 and IL-13 to be higher in IL-23p19/
mice was observed although it was not statistically signiﬁcant.Peritoneal IL-23 production correlates with antigen-speciﬁc serum
immunoglobulin levels
We hypothesized that the opposite effects of IL-23 on allergic
airway inﬂammation in the OVA and HDMmodels were due to site-
speciﬁc differences in IL-23 expression. We ﬁrst examined IL-23
synthesis in the peritoneal cavity upon allergen sensitization.
Peritoneal injection of OVA with alum adjuvant induced localmin (OVA, a) or house dust mite antigen (HDM, b) injection. The peritoneal cavity was
naïve mice. Antigen-speciﬁc IgG1 levels in OVA- (c) or HDM- (d) sensitized mice in sera
IL-23/) mice (n ¼ 6e12). Mean þ SEM. #P < 0.05 compared to wild-type mice.
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HDM did not increase IL-23 levels in the peritoneal cavity (Fig. 3a,
b). IL-6 and IL-10 were also released in the peritoneal cavity 3 h
after OVA administration.
Repeated injection of antigen into the peritoneal cavity for
sensitization, either OVA in conjunction with alum or HDM,
induced the production of allergen-speciﬁc IgG1 in serum. How-
ever, the serum levels of OVA-specific IgG1 were reduced in IL-
23p19/ mice, whereas HDM-specific IgG1 showed no difference
between IL-23p19/ and wild-type mice (Fig. 3c, d). These results
also support the idea that sensitization to OVA, but not to HDM, is
promoted by IL-23.
Pulmonary expression of IL-23 and IL-17A negatively regulates
asthmatic responses
Next, we investigated gene expression of IL-23p19 in the airways
in response to OVA or HDM challenge. Exposure to aerosolized OVA
did not alter IL-23p19 mRNA expression in the lungs (Fig. 4a),
whereas nasal administration of HDM induced and maintainedFig. 4. IL-23p19 mRNA expression in the lungs. Mice were sensitized to OVA (a) or HDM (b)
group). IL-17A mRNA expression in the lungs of wild-type (c) or IL-23p19/ (d) mice after a
count in bronchoalveolar lavage ﬂuid from wild-type (open bars) or IL-17A/ (closed bars)enhanced expression of pulmonary IL-23p19 mRNA for up to 10
days (Fig. 4b). Induction of IL-23 in the airways was associated with
concomitant expression of IL-17A in the lungs, which negatively
regulated eosinophilic inﬂammation. IL-17A mRNAwas induced by
administration of HDM in wild-type, but not in IL-23p19/ mice
(Fig. 4c, d). IL-17A deﬁciency induced a more prominent recruit-
ment of eosinophils in the airways after HDM challenges as IL-23
deﬁciency did (Fig. 4e).
Discussion
In the present study, we demonstrate opposing roles of IL-23 in
two murine models of asthma; IL-23 deﬁciency protected mice
from OVA-induced allergic responses, but, rather, exacerbated
HDM-induced eosinophilic inﬂammation.
The pro-allergic effects of IL-23 on the promotion of Th2 cell
differentiation and related cytokine production are well described
in murine models of asthma using OVA as the allergen.9,15,20e22
Administration of anti-IL-23-neutralizing antibodies,9,22 silencing
of IL-23 expression by a small hairpin RNA21,, a peptide-basedthen exposed to phosphate buffered saline (PBS) or antigen as indicated (n ¼ 3 for each
single exposure to HDM (n ¼ 3). *P < 0.05 compared to the PBS group. (e) Eosinophil
mice. Mean þ SEM. *P < 0.05 compared to wild-type mice.
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suppress the induction of OVA-speciﬁc IgE, eosinophilic airway
inﬂammation, and cytokine synthesis including IL-4, IL-5, IL-13,
and IL-17. The role of IL-23 is further supported by a clinical
observation that serum IL-23 levels are inversely correlated with
lung functions in asthmatic children.23 These ﬁndings are in
accordance with our data in the OVA-induced asthma model;
eosinophil accumulation and IL-5/IL-13 synthesis in the lungs as
well as OVA-speciﬁc IgG1 production were signiﬁcantly suppressed
in IL-23p19/ mice.
In contrast, HDM-driven allergic airway inﬂammation was
rather enhanced in the absence of IL-23 or IL-23-dependent syn-
thesis of IL-17A (Figs. 2, 4). Other reports have shown that IL-23 and
IL-17A negatively regulate eosinophilic airway inﬂammation under
certain conditions, especially in the presence of infectious patho-
gens such as rhinovirus or fungi, which induce robust IL-23
expression in the lungs.17,24 In these models, blocking IL-17A sig-
nals enhances eosinophilic airway inﬂammation, as observed in our
HDM-induced model.17,24,25 Furthermore, exogenously-
administered IL-17A directly acts as a negative regulator of
allergic asthma.16,26,27 Importantly, the dose and cellular source of
IL-17A is crucial to determine whether the cytokine acts as a pos-
itive or a negative regulator in allergic inﬂammation. Higher doses
of IL-17A or gd T cells suppress eosinophil recruitment to the air-
ways, whereas lower doses of IL-17A or ab T cell-derived cytokines
co-operate with Th2 cytokines to enhance airway eosinophilia.26,28
These data are consistent with the results observed in the HDM-
induced model that was associated with enhanced synthesis of
IL-17A in the lungs.
Targeting IL-23 and IL-17A has been suggested as a therapeutic
approach for severe cases of asthma refractory to corticosteroids.
Clinical asthma, however, is not induced by sensitization to a
simple protein antigen, such as OVA, but by exposure to protease
antigens, such as HDM and fungi, or in association with a viral
infection that might induce high levels of IL-23/IL-17A expression
and reduce Th17 cells in the airways. That may explain why sys-
temic administration of an anti-IL-17A antibody failed to improve
asthma symptoms in a clinical trial.29 A novel approach that
selectively inhibits IL-23 signaling toward Th17 differentiation or
proliferation could be an effective therapeutic approach to over-
come this problem.
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